Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Treon, SP (author)

Branagan, AR (author)

Ioakimidis, L (author)

Soumerai, JD (author)

Patterson, CJ (author)

Turnbull, B (author)

Wasi, P (author)

Emmanouilides, C (author)

Frankel, SR (author)

Lister, A (author)

Morel, P (author)

Matous, J (author)

Gregory, SA (author)

(creator_code:org_t)

American Society of Hematology, 2009
2009
English.
In: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 113:16, s. 3673-3678

Related links:: https://europepmc.or...; show more...; http://kipublication...; https://doi.org/10.1...; show less...

Abstract Subject headings

We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m2 per day for 5 days) of fludarabine and 8 infusions (375 mg/m2 per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a very good partial response (P = .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non–Pneumocystis carinii pneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.

By the author/editor: Treon, SP; Branagan, AR; Ioakimidis, L; Soumerai, JD; Patterson, CJ; Turnbull, B; show more...; Wasi, P; Emmanouilides, C; Frankel, SR; Lister, A; Morel, P; Matous, J; Gregory, SA; Kimby, E; show less...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.